Drugs / rDEN2∆30-7169
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02317900 | Dec 2014 → Nov 2016 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN2∆30-7169 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02317900 ↗ |
| Modality | Vaccine | “rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus.” NCT02317900 ↗ |
| Route | Subcutaneous | “It will be delivered by subcutaneous injection in the deltoid region of the upper arm.” NCT02317900 ↗ |